Brentuximab-话题@MedSci - 梅斯（MedSci）

#Brentuximab#

21篇内容 | 1641人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1423363, encodeId=15f11423363dd, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=J Clin Oncol：Brentuximab Vedotin联合AVD一线治疗早期不良霍奇金淋巴瘤的疗效优于标准疗法, objectType=article, longId=734317, objectId=5093e34317c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5093e34317c1, replyNumber=0, likeNumber=97, createdTime=2022-08-05, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5093e34317c1, moduleTitle=J Clin Oncol：Brentuximab Vedotin联合AVD一线治疗早期不良霍奇金淋巴瘤的疗效优于标准疗法, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5093e34317c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423362, encodeId=588b1423362c6, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=Blood：Brentuximab vedotin联合化疗治疗ALK+间变性大细胞淋巴瘤, objectType=article, longId=213718, objectId=fd62213e1849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd62213e1849, replyNumber=0, likeNumber=70, createdTime=2021-07-06, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd62213e1849, moduleTitle=Blood：Brentuximab vedotin联合化疗治疗ALK+间变性大细胞淋巴瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fd62213e1849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423361, encodeId=058314233613b, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=JCO：Brentuximab Vedotin可显著减少高危型HL儿童患者的放疗剂量且不影响疗效, objectType=article, longId=209902, objectId=2b4f20990217, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b4f20990217, replyNumber=0, likeNumber=63, createdTime=2021-04-14, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b4f20990217, moduleTitle=JCO：Brentuximab Vedotin可显著减少高危型HL儿童患者的放疗剂量且不影响疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2b4f20990217)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423360, encodeId=f578142336033, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准, objectType=article, longId=194256, objectId=5af31942566d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5af31942566d, replyNumber=0, likeNumber=110, createdTime=2020-05-18, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5af31942566d, moduleTitle=喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5af31942566d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423359, encodeId=183e142335958, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=马军教授：HL革命性药物Brentuximab vedotin联合其他药物有望进一步提升疗效, objectType=article, longId=179923, objectId=61081e992379, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61081e992379, replyNumber=0, likeNumber=85, createdTime=2019-09-25, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61081e992379, moduleTitle=马军教授：HL革命性药物Brentuximab vedotin联合其他药物有望进一步提升疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=61081e992379)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423358, encodeId=f5351423358ea, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=刘澎教授：Brentuximab vedotin疗效不受限于CD30表达水平，前景广阔, objectType=article, longId=174409, objectId=3ff21e440907, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ff21e440907, replyNumber=0, likeNumber=68, createdTime=2019-06-30, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ff21e440907, moduleTitle=刘澎教授：Brentuximab vedotin疗效不受限于CD30表达水平，前景广阔, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3ff21e440907)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423357, encodeId=26af142335e6e, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=Brentuximab Vedotin在霍奇金淋巴瘤中疗效显著，联合免疫治疗将带来更大突破, objectType=article, longId=168996, objectId=019516899631, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=019516899631, replyNumber=0, likeNumber=89, createdTime=2019-06-24, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=019516899631, moduleTitle=Brentuximab Vedotin在霍奇金淋巴瘤中疗效显著，联合免疫治疗将带来更大突破, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=019516899631)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423356, encodeId=5fcf1423356ee, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=Brentuximab vedotin联合用药有效改善复发/难治霍奇金淋巴瘤预后, objectType=article, longId=168147, objectId=52db16814e29, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52db16814e29, replyNumber=0, likeNumber=80, createdTime=2019-06-13, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52db16814e29, moduleTitle=Brentuximab vedotin联合用药有效改善复发/难治霍奇金淋巴瘤预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=52db16814e29)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423355, encodeId=c7fd14233557a, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=brentuximab vedotin治疗淋巴瘤优势显著，不受CD30表达限制, objectType=article, longId=167948, objectId=c2f816e9487a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2f816e9487a, replyNumber=0, likeNumber=62, createdTime=2019-06-11, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2f816e9487a, moduleTitle=brentuximab vedotin治疗淋巴瘤优势显著，不受CD30表达限制, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c2f816e9487a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423354, encodeId=7b88142335485, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=ASCO 2019：Brentuximab vedotin治疗淋巴瘤优势显著，不依赖CD30表达, objectType=article, longId=167885, objectId=c23216e88573, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c23216e88573, replyNumber=0, likeNumber=70, createdTime=2019-06-10, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c23216e88573, moduleTitle=ASCO 2019：Brentuximab vedotin治疗淋巴瘤优势显著，不依赖CD30表达, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c23216e88573)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423353, encodeId=b7441423353ab, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=Blood：Brentuximab Vedotin+CHP一线治疗外周T细胞淋巴瘤5年结局喜人：客观反应率高达100%！, objectType=article, longId=138647, objectId=e39113864ec6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e39113864ec6, replyNumber=0, likeNumber=45, createdTime=2018-05-21, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e39113864ec6, moduleTitle=Blood：Brentuximab Vedotin+CHP一线治疗外周T细胞淋巴瘤5年结局喜人：客观反应率高达100%！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e39113864ec6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423352, encodeId=11991423352f4, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=Blood：Brentuximab vedotin联合苯达莫司汀作为一线补救疗法用于复发性/难治性HL的疗效和安全性, objectType=article, longId=137013, objectId=ee2913e013e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee2913e013e6, replyNumber=0, likeNumber=73, createdTime=2018-05-04, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee2913e013e6, moduleTitle=Blood：Brentuximab vedotin联合苯达莫司汀作为一线补救疗法用于复发性/难治性HL的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ee2913e013e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423351, encodeId=c0e414233511f, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性, objectType=article, longId=131784, objectId=6781131e84a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6781131e84a3, replyNumber=0, likeNumber=52, createdTime=2018-03-09, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6781131e84a3, moduleTitle=Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6781131e84a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423350, encodeId=77e414233504b, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=姜文奇教授：Brentuximab Vedotin联合AVD一线治疗中晚期霍奇金淋巴瘤可显著改善无复发生存, objectType=article, longId=123411, objectId=11981234112e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11981234112e, replyNumber=0, likeNumber=113, createdTime=2017-12-16, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11981234112e, moduleTitle=姜文奇教授：Brentuximab Vedotin联合AVD一线治疗中晚期霍奇金淋巴瘤可显著改善无复发生存, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=11981234112e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423349, encodeId=da701423349d5, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=Blood：Brentuximab vedotin联合nivolumab用于治疗霍奇金淋巴瘤的效果。, objectType=article, longId=123243, objectId=fe1312324341, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe1312324341, replyNumber=0, likeNumber=71, createdTime=2017-12-14, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe1312324341, moduleTitle=Blood：Brentuximab vedotin联合nivolumab用于治疗霍奇金淋巴瘤的效果。, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fe1312324341)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423348, encodeId=37551423348fc, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案, objectType=article, longId=123207, objectId=4dfc12320e42, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dfc12320e42, replyNumber=0, likeNumber=58, createdTime=2017-12-14, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dfc12320e42, moduleTitle=【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4dfc12320e42)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423347, encodeId=ee98142334eba, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=Blood：brentuximab vedotin联合达卡巴嗪或苯达莫司汀用于HL老年患者的安全性和治疗效果。, objectType=article, longId=116500, objectId=e5fb11650085, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5fb11650085, replyNumber=0, likeNumber=70, createdTime=2017-10-19, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5fb11650085, moduleTitle=Blood：brentuximab vedotin联合达卡巴嗪或苯达莫司汀用于HL老年患者的安全性和治疗效果。, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e5fb11650085)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423346, encodeId=e62014233465c, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=Blood：brentuximab vedotin治疗复发或难治性系统性间变性大细胞淋巴瘤的2期临床报告, objectType=article, longId=115405, objectId=751111540543, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=751111540543, replyNumber=0, likeNumber=73, createdTime=2017-10-09, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=751111540543, moduleTitle=Blood：brentuximab vedotin治疗复发或难治性系统性间变性大细胞淋巴瘤的2期临床报告, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=751111540543)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423345, encodeId=e9c5142334572, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=Haematologica：Brentuximab vedotin治疗复发/难治性系统性间变性大细胞淋巴瘤的大型观察性研究（意大利真实世界研究）, objectType=article, longId=107875, objectId=aa2c10e8756a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa2c10e8756a, replyNumber=0, likeNumber=73, createdTime=2017-08-07, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa2c10e8756a, moduleTitle=Haematologica：Brentuximab vedotin治疗复发/难治性系统性间变性大细胞淋巴瘤的大型观察性研究（意大利真实世界研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=aa2c10e8756a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423344, encodeId=8ab01423344c2, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, objectTitle=Lancet：Brentuximab vedotin治疗霍奇金淋巴瘤的研究, objectType=article, longId=48877, objectId=c20f488e7cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c20f488e7cd, replyNumber=0, likeNumber=75, createdTime=2015-04-03, rootId=0, userName=photoman, userId=f3be3772079, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c20f488e7cd, moduleTitle=Lancet：Brentuximab vedotin治疗霍奇金淋巴瘤的研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c20f488e7cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Brentuximab

2020-05-29

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

J Clin Oncol：Brentuximab Vedotin联合AVD一线治疗早期不良霍奇金淋巴瘤的疗效优于标准疗法

2022-08-05

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

Blood：Brentuximab vedotin联合化疗治疗ALK+间变性大细胞淋巴瘤

2021-07-06

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

JCO：Brentuximab Vedotin可显著减少高危型HL儿童患者的放疗剂量且不影响疗效

2021-04-14

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准

2020-05-18

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

马军教授：HL革命性药物Brentuximab vedotin联合其他药物有望进一步提升疗效

2019-09-25

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

刘澎教授：Brentuximab vedotin疗效不受限于CD30表达水平，前景广阔

2019-06-30

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

Brentuximab Vedotin在霍奇金淋巴瘤中疗效显著，联合免疫治疗将带来更大突破

2019-06-24

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

Brentuximab vedotin联合用药有效改善复发/难治霍奇金淋巴瘤预后

2019-06-13

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

brentuximab vedotin治疗淋巴瘤优势显著，不受CD30表达限制

2019-06-11

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

ASCO 2019：Brentuximab vedotin治疗淋巴瘤优势显著，不依赖CD30表达

2019-06-10

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

Blood：Brentuximab Vedotin+CHP一线治疗外周T细胞淋巴瘤5年结局喜人：客观反应率高达100%！

2018-05-21

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

Blood：Brentuximab vedotin联合苯达莫司汀作为一线补救疗法用于复发性/难治性HL的疗效和安全性

2018-05-04

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性

2018-03-09

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

姜文奇教授：Brentuximab Vedotin联合AVD一线治疗中晚期霍奇金淋巴瘤可显著改善无复发生存

2017-12-16

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

Blood：Brentuximab vedotin联合nivolumab用于治疗霍奇金淋巴瘤的效果。

2017-12-14

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案

2017-12-14

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

Blood：brentuximab vedotin联合达卡巴嗪或苯达莫司汀用于HL老年患者的安全性和治疗效果。

2017-10-19

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

Blood：brentuximab vedotin治疗复发或难治性系统性间变性大细胞淋巴瘤的2期临床报告

2017-10-09

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

Haematologica：Brentuximab vedotin治疗复发/难治性系统性间变性大细胞淋巴瘤的大型观察性研究（意大利真实世界研究）

2017-08-07

photoman (审核中...)

前往app查看评论内容

#Brentuximab#

Lancet：Brentuximab vedotin治疗霍奇金淋巴瘤的研究

2015-04-03

科室
- - 订阅+
  - 更多科室
工具
服务